Ra Pharmaceuticals

Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs. It was founded in 2008 and headquartered in Cambridge, Massachusetts.

Is  (RARX) Outperforming Other Medical Stocks This Year?

Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?

Ra Pharmaceuticals (RARX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry

Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.

Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

Bed Bath & Beyond

Freeport-McMoRan

One of these stocks was pushed higher after it revealed who will next sit in the CEO's chair.

Why Bed Bath & Beyond, Ra Pharmaceuticals, and Freeport-McMoRan Jumped Today

Ra Pharmaceuticals (NRARX) is seeing its stock take off on Thursday following news of a deal with UCB (UCBJF) valued at $2.10 billion.

Ra Pharmaceuticals News: RARX Stock Flies 100% on $2.1 Billion UCB Deal

OncoSec Medical

ProPetro Hld

Markets soar on US-China trade talk optimism.

4 Stocks With More Than 20% Price Increases on Thursday

Ra Pharmaceuticals Inc (NASDAQ: RARX) shares were up 100% Thursday following the announcement of a buyout by Belgian biopharma UCB SA (OTC: UCBJF).

Ra Pharma Stock Doubles On $2.5B Buyout Deal With Belgian Biopharma UCB

Shares make a triple-digit jump after the company announces that it has agreed to be acquired. Here's what investors need to know.

Why Ra Pharmaceuticals Is Skyrocketing Today

Ra Pharmaceuticals Inc. (NASDAQ: RARX) shares more than doubled on Thursday after the announcement that UCB would acquire the firm.

Are Shareholders Getting Enough From the Ra Pharma Acquisition?

Ra Pharma stock rocketed by more than 100% Thursday after Belgium biotech company UCB agreed to acquire it for $2.1 billion. Ra Pharma is working on a treatment for a muscular condition.

This Biotech Stock Just Doubled After Snagging A $2.1 Billion Takeover Deal

Ra Pharmacetuicals delivered strong gains in the last 12 months on the heels of positive phase 2 results of zilucoplan in gMG.

News for Ra Pharmaceuticals Stock (RARX)